Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11

摘要

BackgroundGastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability of dulaglutide at once-weekly doses of 1.5, 3.0, and 4.5?mg.MethodsThe AWARD-11 trial randomized patients to once-weekly dulaglutide 1.5?mg ( n =?612), 3.0?mg ( n =?616), or 4.5?mg ( n =?614) for 52?weeks. Patients started on dulaglutide 0.75?mg for 4?weeks before escalating stepwise every 4?weeks until the final randomized dose was reached. This study analyzes the onsets, incidences, prevalences, and severities of nausea, vomiting, and diarrhea events reported through 52?weeks.ResultsThe highest incidences of nausea (≤?8%), vomiting (≤?2%), and diarrhea (≤?4%) were primarily observed soon after the initiation of dulaglutide treatment at 0.75?mg. Incidence then declined throughout the remainder of the study, even with dose escalation to 1.5, 3.0, and 4.5?mg. Most of these GI TEAEs were mild to moderate in severity, with severe nausea, vomiting, or diarrhea events occurring in?≤?0.6% of patients. Treatment discontinuation due to nausea was low across treatment groups (≤?1.5%).ConclusionsThe tolerability profiles of dulaglutide 3.0?mg and 4.5?mg were consistent with that of the 1.5-mg dose. Patients experiencing GI events were most likely to do so within 2?weeks of treatment initiation, and few patients experienced a new GI event after escalating to the 3.0-mg or 4.5-mg dose. Severe events were infrequent, and when they did occur, no relationship with dose at time of event was observed.